Location History:
- Maharashtra, IN (2014)
- Mumbai, IN (2007 - 2020)
Company Filing History:
Years Active: 2007-2020
Title: Kamlesh Digambar Sawant: Innovator in Pharmaceutical Processes
Introduction
Kamlesh Digambar Sawant is a prominent inventor based in Mumbai, India, known for his significant contributions to the pharmaceutical field. With a portfolio of five patents, he has demonstrated a remarkable ability to innovate processes that enhance drug development and formulation.
Latest Patents
Among his latest inventions, Kamlesh has filed patents for the following breakthrough processes:
1. **Process for preparation of regadenoson and polymorphs thereof** - This patent pertains to a method for preparing Regadenoson and its polymorphs, specifically focusing on Regadenoson Form C.
2. **Process for preparation of Rasagiline and salts thereof** - This invention describes an improved method for synthesizing Rasagiline and its pharmaceutically acceptable salts, along with details regarding the salts and polymorphs involved in the process.
Career Highlights
Throughout his career, Kamlesh has made significant strides in his field by working with reputable companies such as USV Private Limited and Health Science Funding, LLC. His efforts have led to advancements that resonate within the pharmaceutical industry, marking him as a key player in drug formulation technologies.
Collaborations
Kamlesh has collaborated with notable professionals including Dhananjay Govind Sathe and Tushar Anil Naik. These collaborations have likely contributed to the fruitful development of his patents and innovations, showcasing the power of teamwork in achieving groundbreaking results in pharmaceutical research.
Conclusion
In conclusion, Kamlesh Digambar Sawant exemplifies the essence of innovation in pharmaceuticals. His patents not only reflect his ingenuity but also contribute to advancing healthcare solutions. As he continues to work and collaborate with other professionals, his future contributions are anticipated to make a notable impact on the industry.